FDA Grants MarzAA Orphan Drug Designation
FDA granted orphan drug designation to Catalyst Biosciences’ MarzAA for the treatment of Factor VII Deficiency.
Catalyst Biosciences, a research and clinical development biopharmaceutical company, announced on Sept. 28, 2021, that FDA has granted orphan drug designation (ODD) to its lead product candidate, subcutaneous Marzeptacog alfa (activated), or MarzAA, for the treatment of Factor VII Deficiency (FVIID).
MarzAA is a subcutaneously administered next-generation engineered coagulation Factor VII designed for the treatment of episodic bleeding in subjects with rare bleeding disorders. FVIID is a rare condition that interferes with the blood clotting process, resulting in prolonged bleeding.
MarzAA had previously been granted ODD and fast track designation (FTD) for the treatment of another blood disorder, Hemophilia A/B, with inhibitors. Additionally, MarzAA was granted FTD for FVIID treatment by FDA prior to this ODD.
"Receiving a second orphan drug designation in addition to two FTDs for MarzAA demonstrates its potential in treating multiple rare bleeding disorders” said Nassim Usman, president and CEO of Catalyst Biosciences, in a company press release.
Source: Catalyst Biosciences
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
